Veralox Therapeutics logo Veralox Therapeutics
  • About Veralox
    • Meet the Team
  • Our Approach
  • Pipeline
    • Publications
  • Company News
  • Contact

Publications

  • Hematology
  • Diabetes
  • Other
Hematology

12-LOX catalyzes the oxidation of 2-arachidonoyl-lysolipids in the platelets generating eicosanoid-lysolipids that are attenuated by iPLA2γ knockout

Liu et al. J. Biol. Chem. 2020;295:P5307 Read More
Hematology

Synthetic high-density lipoproteins loaded with an antiplatelet drug for efficient inhibition of thrombosis in mice

He et al. Science Advances 2020;6:eabd0130 Read More
Hematology

Targeting 12-Lipoxygenase as a Potential Novel Antiplatelet Therapy

Tourdot et al. Trends in Pharmacol. Sci. 2017;38:P1006 Read More
Hematology

Heparin-induced thrombocytopenia

Arepally. Blood 2017;129:2864 Read More
Hematology

First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion In Vivo With Minimal Effects on Hemostasis

Adili et al. Arterioscl Throm Vasc Biol. 2017;37:1828 Read More
Hematology

Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation

Yeung et al. Blood 2014;124:2271 Read More
Veralox Therapeutics logo
Developing new therapies for life-threatening immuno-inflammatory diseases
Veralox Headquarters
4539 Metropolitan Ct
Frederick, MD 21704
301-360-3502
  • About Veralox
  • Our Approach
  • Pipeline
  • Team
  • Publications
  • Company News
  • Contact

Copyright 2023 | Website design by Wood Street, Inc.